FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Giorgio Scagliotti

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Gene Expression Regulation, Neoplastic

Co-author Network

Publications

TOP 3
Silvia Novello; Ettore Pelosi; Federica Solitro; Tiziana Vavalà; Andrea Veltri; Matteo Giaj Levra; Giorgio V Scagliotti
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Valentina Monica; Domenico Novero; Giulio Rossi; Enrico Ruffini; Giorgio V Scagliotti; Francesco Ardissone; Simone Busso; Luigi Chiusa; Ubaldo Familiari; Mauro Papotti
Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors.
Luisella Righi; Giorgio V Scagliotti; Simona Vatrano; Marco Volante; Paolo De Giuli; Mara Ardine; Susanna Cappia; Alessandra Cuccurullo; Daniela Giachino; Silvia Novello; Mauro Papotti
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Giorgio Scagliotti (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Silvia Novello; Ettore Pelosi; Federica Solitro; Tiziana Vavalà; Andrea Veltri; Matteo Giaj Levra; Giorgio V Scagliotti
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Clinical lung cancer 2013;14(3):230-7.
2013: Valentina Monica; Domenico Novero; Giulio Rossi; Enrico Ruffini; Giorgio V Scagliotti; Francesco Ardissone; Simone Busso; Luigi Chiusa; Ubaldo Familiari; Mauro Papotti
Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors.
Lung cancer (Amsterdam, Netherlands) 2013;79(3):228-35.
2013: Luisella Righi; Giorgio V Scagliotti; Simona Vatrano; Marco Volante; Paolo De Giuli; Mara Ardine; Susanna Cappia; Alessandra Cuccurullo; Daniela Giachino; Silvia Novello; Mauro Papotti
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.
BMC cancer 2013;13():114.
2013: A T Shaw; B J Solomon; A M Varghese; B Y Yeap; M M Awad; D B Costa; J A Engelman; M Mino-Kenudson; V Monica; S Novello; G J Riely; Giorgio V Scagliotti
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(1):59-66.
2012: Matteo Giaj Levra; Silvia Novello; Mauro Papotti; Giorgio V Scagliotti; Axel Le Cesne
Primary pleuropulmonary sarcoma: a rare disease entity.
Clinical lung cancer 2012;13(6):399-407.
2012: Valentina Monica; Barbara Felice; Marina Longo; Mauro Papotti; Giorgio V Scagliotti; Silvia Novello
Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy.
Clinical lung cancer 2012;13(6):416-23.
2012: Giorgio V Scagliotti; Joan H Schiller; Brian Schwartz; Lecia V Sequist; Jean-Charles Soria; Joachim von Pawel; R von Roemeling; Vera Hirsh; Silvia Novello; Alan B Sandler
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Clinical lung cancer 2012;13(5):391-5.
2012: Giorgio V Scagliotti; Oleksandr Sydorenko; Ihor Vynnychenko; Bin Yao; Natividad Martinez Banaclocha; Fiona Blackhall; Tudor-Eliade Ciuleanu; Mircea Dediu; Francesco Galimi; Rinat Galiulin; Yong-Jiang Hei; Yukito Ichinose; Kaoru Kubota; Sheryl McCoy; Zsolt Papai-Szekely; Keunchil Park; Robert Pirker; David R Spigel
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(23):2829-36.
2012: Giorgio V Scagliotti; D Schallier; A J M Schreurs; J R Perez; V Sallo; I Albert; S Barbera; Filippo De Marinis; W Engel-Riedel; P Kosmidis; H-P Kuo; Christian Manegold
Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(8):2082-7.
2012: Egbert F Smit; M A Socinski; Aleksandra Szczesna; Joachim von Pawel; tudor ciuleanu; S C Guba; S Hong; R R Hozak; N A Karaseva; P Lorigan; B P Mullaney; S P Myrand; D Ohannesian; E Powell; Martin Reck; Giorgio V Scagliotti; N Thatcher
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(7):1723-9.
2012: Giorgio V Scagliotti; Paulina Selaru; Janos Strausz; Aleksandra Szczesna; Michael Thomas; Sumitra Thongprasert; Lesley Tye; Joachim von Pawel; Rafal F Wierzbicki; Ke Zhang; Nina Karaseva; Maciej Krzakowski; Anatoly Makhson; Jose Elias Abrao Miziara; Zsolt S Papai; Elsa Dalmau Portulas; Martin Reck; Istvan Albert; Richard C Chao; Ramaswamy Govindan
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(17):2070-8.
2012: Giorgio V Scagliotti; Joachim von Pawel; Silvia Novello; Martin Reck; Joan Andrews; Lucio Crino; Dinesh P de Alwis; Sabine Ermisch; Corinna Eschbach; Juergen R Fischer; Robert Ilaria; Christian Manegold
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(6):1053-7.
2012: Giorgio V Scagliotti; Silvia Novello
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
Cancer treatment reviews 2012;38(4):292-302.
2012: Joseph Treat; Matthew J Monberg; Coleman K Obasaju; Guangbin Peng; Giorgio V Scagliotti; Mark A Socinski
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
Lung cancer (Amsterdam, Netherlands) 2012;76(2):222-7.
2012: Paolo Ceppi; Jessica Giorcelli; Marco Lo Iacono; Mauro Papotti; Marisa Pautasso; Ida Rapa; Luisella Righi; Francesco Ardissone; Andrea Billè; Giorgio V Scagliotti
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
International journal of cancer. Journal international du cancer 2012;130(8):1777-86.
2012: Marco Tampellini; Elisa Sperti; Massimo Aglietta; Irene Alabiso; Oscar Alabiso; Francesco Ardissone; Chiara Baratelli; Elisa Bellini; Alfredo Berruti; Erica Bertona; Raffaella Bitossi; Maria Pia Brizzi; Anna Ferrero; Laura Forti; Francesco Leone; S Miraglia; Azzurra Ottone; Giorgio V Scagliotti
The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study.
The oncologist 2012;17(11):1430-8.
2011: Rabab M Gaafar; Baktiar Hasan; Demetris Papamichael; Giorgio V Scagliotti; Veerle F Surmont; Valter Torri; Rob J Van Klaveren; Jan P van Meerbeeck; John J Welch
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
European journal of cancer (Oxford, England : 1990) 2011;47(15):2331-40.
2011: Luisella Righi; Giulio Rossi; Giorgio V Scagliotti; Giuseppe Pelosi; Mattia Barbareschi; Alberto Cavazza; Alessandro Fornari; Paolo Graziano; Mauro Papotti
Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation.
Cancer 2011;117(15):3416-23.
2011: Marco Lo Iacono; Valentina Monica; Silvia Saviozzi; Paolo Ceppi; Enrico Bracco; Mauro Papotti; Giorgio V Scagliotti
p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(3):473-81.
2011: Suresh Senan; F Cardenal; Johan Vansteenkiste; J Stigt; F Akyol; W De Neve; J Bakker; J-M Dupont; Giorgio V Scagliotti; U Ricardi; J P van Meerbeeck
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(3):553-8.
2011: Marco Lo Iacono; Valentina Monica; Mauro Papotti; Silvia Saviozzi; Enrico Bracco; Paolo Ceppi; Giorgio V Scagliotti
Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation.
Journal of translational medicine 2011;9():100.
2011: Giorgio V Scagliotti; Thomas Brodowicz; Frances A Shepherd; Christoph Zielinski; Johan Vansteenkiste; Christian Manegold; Lorinda Simms; Frank Fossella; Katherine Sugarman; Chandra P Belani
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(1):64-70.
2010: Paolo Ceppi; Giridhar Mudduluru; Regalla Kumarswamy; Ida Rapa; Giorgio V Scagliotti; Mauro Papotti; Heike Allgayer
Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.
Molecular cancer research : MCR 2010;8(9):1207-16.
2010: Andrea Wang-Gillam; Kristina Williams; Silvia Novello; Feng Gao; Giorgio V Scagliotti; Ramaswamy Govindan
Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3803-7.
2010: Giorgio V Scagliotti; Paul Germonpré; Leon Bosquée; Johan Vansteenkiste; R Gervais; David Planchard; Martin Reck; Filippo De Marinis; Jin Soo Lee; Keunchil Park; Bonne Biesma; Steven Gans; Rodryg Ramlau; Aleksandra Szczesna; A Makhson; G Manikhas; Bruno Morgan; Y Zhu; Kai C Chan; Joachim von Pawel
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2010;68(3):420-6.
2010: Luisella Righi; Mauro G Papotti; Paolo Ceppi; Andrea Billè; Elisa Bacillo; Luca Molinaro; Enrico Ruffini; Giorgio V Scagliotti; Giovanni Selvaggi
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(9):1534-9.
2010: Paolo Ceppi; Mauro Papotti; Giorgio V Scagliotti
New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS.
Advances in medical sciences 2010;55(1):22-5.
2010: Giorgio V Scagliotti; Ramaswamy Govindan
Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
The oncologist 2010;15(5):436-46.
2009: Giorgio V Scagliotti; Filippo De Marinis; Massimo Rinaldi; Lucio Crinò; Cesare Gridelli; Sergio Ricci; Yan D Zhao; Astra M Liepa; Patrick Peterson; Maurizio Tonato
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(12):1568-71.
2009: Silvia Novello; Alfredo Falcone; Lucio Crinò; Massimo Rinaldi; Mario Nardi; Filippo De Marinis; Maurizio Tonato; Carmelo Tibaldi; Angelo Tinazzi; Francesca Russo; Nicoletta Grassivaro; Giorgio V Scagliotti
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2009;66(3):327-32.
2009: Giovanni Selvaggi; Giorgio V Scagliotti
Histologic subtype in NSCLC: does it matter?
Oncology (Williston Park, N.Y.) 2009;23(13):1133-40.
2009: Silvia Novello; Giorgio V Scagliotti; R Rosell; Mark A Socinski; Julie R Brahmer; J Atkins; C Pallares; R Burgess; L Tye; P Selaru; E Wang; R Chao; R Govindan
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
British journal of cancer 2009;101(9):1543-8.
2009: Paolo Ceppi; Mauro Papotti; Valentina Monica; Marco Lo Iacono; Silvia Saviozzi; Marisa Pautasso; Silvia Novello; Stefano Mussino; Enrico Bracco; Marco Volante; Giorgio V Scagliotti
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Molecular cancer therapeutics 2009;8(11):3066-74.
2009: Giorgio V Scagliotti; Keunchil Park; Shekar Patil; Janusz Rolski; Tuncay Goksel; Renato Martins; Steven J M Gans; Carla Visseren-Grul; Patrick Peterson
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
European journal of cancer (Oxford, England : 1990) 2009;45(13):2298-303.
2009: Paola Cassoni; Lorenzo Daniele; Elena Maldi; Luisella Righi; Veronica Tavaglione; Silvia Novello; Marco Volante; Giorgio V Scagliotti; Mauro Papotti
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases.
Histopathology 2009;55(1):20-7.
2009: Lorenzo Daniele; Paola Cassoni; Elisa Bacillo; Susanna Cappia; Luisella Righi; Marco Volante; Fabrizio Tondat; Giorgio Inghirami; Anna Sapino; Giorgio V Scagliotti; Mauro Papotti; Silvia Novello
Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(6):684-8.
2009: Valentina Monica; Paolo Ceppi; Luisella Righi; Veronica Tavaglione; Marco Volante; Giuseppe Pelosi; Giorgio V Scagliotti; Mauro Papotti
Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009;22(5):709-17.
2009: Silvia Saviozzi; Paolo Ceppi; Silvia Novello; Paolo Ghio; Marco Lo Iacono; Piero Borasio; Alberto Cambieri; Marco Volante; Mauro Papotti; Raffaele A Calogero; Giorgio V Scagliotti
Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways.
Cancer research 2009;69(8):3390-6.
2009: Giorgio V Scagliotti; Marina Longo; Silvia Novello
Nonsmall cell lung cancer in never smokers.
Current opinion in oncology 2009;21(2):99-104.
2009: Giorgio V Scagliotti; Paolo Ceppi; Enrica Capelletto; Silvia Novello
Updated clinical information on multitargeted antifolates in lung cancer.
Clinical lung cancer 2009;10 Suppl 1():S35-40.
2009: Giorgio V Scagliotti; Nasser Hanna; Frank Fossella; Katherine Sugarman; Johannes Blatter; Patrick Peterson; Lorinda Simms; Frances A Shepherd
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
The oncologist 2009;14(3):253-63.
2008: Martin Früh; Estelle Rolland; Jean-Pierre Pignon; Lesley Seymour; Keyue Ding; Hélène Tribodet; Timothy Winton; Thierry Le Chevalier; Giorgio V Scagliotti; Jean Yves Douillard; Stephen Spiro; Frances A Shepherd
Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3573-81.
2008: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3552-9.
2008: Giorgio V Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David R Gandara
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3543-51.
2008: Paul Taylor; Bruno Castagneto; Graham Dark; Maurizio Marangolo; Giorgio V Scagliotti; Rob J van Klaveren; Roberto Labianca; Monika Serke; W Schuette; Jan P van Meerbeeck; David Heigener; Yushan Liu; Susumu Adachi; Johannes Blatter; Joachim von Pawel
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(7):764-71.
2008: Susanna Cappia; Luisella Righi; Dario Mirabelli; Paolo Ceppi; Elisa Bacillo; Francesco Ardissone; Luca Molinaro; Giorgio V Scagliotti; Mauro Papotti
Prognostic role of osteopontin expression in malignant pleural mesothelioma.
American journal of clinical pathology 2008;130(1):58-64.
2008: Paolo Ceppi; Marina Longo; Marco Volante; Silvia Novello; Susanna Cappia; Elisa Bacillo; Giovanni Selvaggi; Silvia Saviozzi; Raffaele Calogero; Mauro Papotti; Giorgio V Scagliotti
Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6):583-9.
2008: Paolo Ceppi; Marco Volante; Anna Ferrero; Luisella Righi; Ida Rapa; Rosj Rosas; Alfredo Berruti; Luigi Dogliotti; Giorgio V Scagliotti; Mauro Papotti
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(4):1059-64.
2008: Mark A Socinski; Silvia Novello; Julie R Brahmer; Rafael Rosell; Jose M Sanchez; Chandra P Belani; Ramaswamy Govindan; James N Atkins; Heidi H Gillenwater; Cinta Pallares; Lesley Tye; Paulina Selaru; Richard C Chao; Giorgio V Scagliotti
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):650-6.
2008: Giorgio V Scagliotti; Giovanni Selvaggi
New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Clinical lung cancer 2008;9 Suppl 3():S122-8.
2007: Marco Volante; Silvia Saviozzi; Ida Rapa; Paolo Ceppi; Susanna Cappia; Raffaele A Calogero; Silvia Novello; Piero Borasio; Mauro Papotti; Giorgio V Scagliotti
Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Cancer 2007;110(6):1321-8.
2007: Giorgio V Scagliotti
Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 10():x32-41.
2007: Valerio Marci; Marco Volante; Susanna Cappia; Luisella Righi; Corrado Novello; Giorgio V Scagliotti; Elisabeth Brambilla; Mauro Papotti
Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma.
Virchows Archiv : an international journal of pathology 2007;451(3):729-36.
2007: Giorgio V Scagliotti
Multimodality approach to early-stage non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2007;57 Suppl 2():S6-11.
2007: Luisella Righi; Marco Volante; Ida Rapa; Giorgio V Scagliotti; Mauro Papotti
Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data.
Virchows Archiv : an international journal of pathology 2007;451 Suppl 1():S51-9.
2007: Giorgio V Scagliotti
Optimizing chemotherapy for patients with advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2 Suppl 2():S86-91.
2007: Daniela Giachino; Paolo Ghio; Silvia Regazzoni; Giorgia Mandrile; Silvia Novello; Giovanni Selvaggi; Dario Gregori; Mario DeMarchi; Giorgio V Scagliotti
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2876-81.
2007: Silvia Novello; P Bruzzi; Carla Barone; R Buosi; A Masotti; G Michetti; M Fioretti; Santi Barbera; M Spatafora; Lucia Garetto; P Mazzanti; Vincenzo Dongiovanni; Giovanni Selvaggi; Lucio Crinò; Giorgio V Scagliotti
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(5):903-8.
2007: Giorgio V Scagliotti; Giovanni Selvaggi
Emerging drugs for mesothelioma.
Expert opinion on emerging drugs 2007;12(1):127-37.
2007: António Araújo; Ricardo Ribeiro; Isabel Azevedo; Ana Coelho; Marta Soares; Berta Sousa; Daniela Pinto; Carlos Lopes; Rui Medeiros; Giorgio V Scagliotti
Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
The oncologist 2007;12(2):201-10.
2007: Elena Gelormino; Eva Pagano; Silvana Appiano; Manuela Ceccarelli; Libero Ciuffreda; Alessandro Comandone; enzo farina; Franco Merletti; Antonio Mussa; Angelo Penna; Antonio Ponti; Ida Raciti; Giorgio V Scagliotti; Nereo Segnan; Carlo Senore; Piero Sismondi; Paolo Vineis; Oscar Bertetto; Giovannino Ciccone
[Adapting clinical practice guidelines to a regional oncology network: the Piedmont experience].
Epidemiologia e prevenzione 2007;31(1):25-33.
2007: Gabriella Zecchina; Paolo Ghio; Sandra Bosio; Marta Cravino; Clara Camaschella; Giorgio V Scagliotti
Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer.
Clinical lung cancer 2007;8(4):264-7.
2006: Paolo Ceppi; Marco Volante; Silvia Novello; Ida Rapa; K D Danenberg; P V Danenberg; A Cambieri; G Selvaggi; Silvia Saviozzi; Raffaele A Calogero; Mauro Papotti; Giorgio V Scagliotti
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(12):1818-25.
2006: Mark G Kris; Giuseppe Giaccone; Angela Davies; Masahiro Fukuoka; David H Garfield; Jacek Jassem; Elisabeth Quoix; Alan B Sandler; Giorgio V Scagliotti; Jan P van Meerbeeck; Howard West
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9 Suppl):S32-6.
2006: Mauro Papotti; Thea Kalebic; Marco Volante; Luigi Chiusa; Elisa Bacillo; Susanna Cappia; Paolo Lausi; Silvia Novello; Piero Borasio; Giorgio V Scagliotti
Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4818-24.
2006: Paolo Ceppi; Marco Volante; Silvia Saviozzi; Ida Rapa; Silvia Novello; Alberto Cambieri; Marco Lo Iacono; Susanna Cappia; Mauro Papotti; Giorgio V Scagliotti
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.
Cancer 2006;107(7):1589-96.
2006: Giorgio V Scagliotti
Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?
Nature clinical practice. Oncology 2006;3(6):294-5.
2006: Ida Rapa; Marco Volante; Susanna Cappia; Rosj Rosas; Giorgio V Scagliotti; Mauro Papotti
Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.
American journal of clinical pathology 2006;125(6):847-54.
2006: Federico Cappuzzo; Silvia Novello; Filippo De Marinis; Giovanni Selvaggi; Giorgio V Scagliotti; Fausto Barbieri; M Maur; Maximilian Papi; E Pasquini; Stefania Bartolini; L Marini; Lucio Crinò
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2006;52(3):319-25.
2006: Giorgio V Scagliotti
Proteasome inhibitors in lung cancer.
Critical reviews in oncology/hematology 2006;58(3):177-89.
2006: Giorgio V Scagliotti; Aleksandra Szczesna; Rodryg Ramlau; F Cardenal; Karin Mattson; nico van zandwijk; A Price; B Lebeau; J Debus; Christian Manegold
Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer.
British journal of cancer 2006;94(10):1375-82.
2006: Giorgio V Scagliotti; Silvia Novello
Current status of adjuvant chemotherapy in NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v62-3.
2006: Paolo Ghio; Susanna Cappia; Giovanni Selvaggi; Silvia Novello; Paulo Lausi; Gabriella Zecchina; Marno Papotti; Piero Borasio; Giorgio V Scagliotti
Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer.
Clinical lung cancer 2006;7(6):395-400.
2006: Giorgio V Scagliotti; Silvia Novello
The way forward: new drugs and new therapeutic strategies in lung cancer therapy.
Clinical lung cancer 2006;7 Suppl 4():S109-10.
2006: Silvia Bovio; Aldo Cataldi; Giuseppe Reimondo; Paola Sperone; Silvia Novello; Alfredo Berruti; Piero Borasio; Cesare Fava; Luigi Dogliotti; Giorgio V Scagliotti; Alberto Angeli; Massimo Terzolo
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series.
Journal of endocrinological investigation 2006;29(4):298-302.
2006: Giorgio V Scagliotti; Giovanni Selvaggi
Antimetabolites and cancer: emerging data with a focus on antifolates.
Expert opinion on therapeutic patents 2006;16(2):189-200.
2006: Silvia Saviozzi; Francesca Cordero; Marco Lo Iacono; Silvia Novello; Giorgio V Scagliotti; Raffaele A Calogero
Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer.
BMC cancer 2006;6():200.
2005: Giorgio V Scagliotti
An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer.
Expert opinion on pharmacotherapy 2005;6(16):2855-66.
2005: Giovanni Selvaggi; Giorgio V Scagliotti
Management of bone metastases in cancer: a review.
Critical reviews in oncology/hematology 2005;56(3):365-78.
2005: Luciano Cardinale; Giancarlo Cortese; Piero Borasio; Luigi Dogliotti; Fabrizio Ferraris; Silvia Novello; Fabio Perotto; Giorgio V Scagliotti; Cesare Fava
Low dose CT in early lung cancer diagnosis: Prevalence data.
La Radiologia medica 2005;110(5-6):532-43.
2005: Giorgio V Scagliotti
Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;50 Suppl 1():S18-9.
2005: Giorgio V Scagliotti; Egbert Smit; Lionel Bosquee; Mary O'Brien; Andrea Ardizzoni; Peter Zatloukal; Wilfried Eberhardt; Maartje Smid-Geirnaerdt; Hein G de Bruin; Sonia Dussenne; Catherine Legrand; Giuseppe Giaccone
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).
Lung cancer (Amsterdam, Netherlands) 2005;50(1):91-6.
2005: Silvia Novello; Cesare Fava; Piero Borasio; Luigi Dogliotti; Giancarlo Cortese; B Crida; Giovanni Selvaggi; Paolo Lausi; M P Brizzi; Paola Sperone; Luciano Cardinale; Fabrizio Ferraris; Fabio Perotto; Adriano M Priola; Giorgio V Scagliotti
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(10):1662-6.
2005: Federico Cappuzzo; Silvia Novello; Filippo De Marinis; Vittorio Franciosi; M Maur; Anna Ceribelli; Vito Lorusso; Fausto Barbieri; Luciano Castaldini; Enrico Crucitta; L Marini; Stefania Bartolini; Giorgio V Scagliotti; Lucio Crinò
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
British journal of cancer 2005;93(1):29-34.
2005: Giorgio V Scagliotti
The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):5011s-5016s.
2005: Thomas J Lynch; Jeffrey A. Bogart; Walter Curran; Malcolm M DeCamp; David R Gandara; Glenwood Goss; Claudia I Henschke; James R Jett; Bruce E Johnson; Karen L Kelly; Thierry Le Chevalier; James L Mulshine; Giorgio V Scagliotti; Joan H Schiller; Alice Shaw; Nick Thatcher; Everett E Vokes; Douglas E Wood; Carol Hart
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):4981s-4983s.
2005: Silvia Novello; Adrian Kielhorn; G Stynes; Giovanni Selvaggi; Filippo De Marinis; Antonio Maestri; P Foggi; Dominic Tilden; Maurizio Tonato; Lucio Crinò; Massimo Rinaldi; A M Migliorino; Giorgio V Scagliotti
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
Lung cancer (Amsterdam, Netherlands) 2005;48(3):379-87.
2005: Giorgio V Scagliotti
Which should be added to cisplatin for advanced non-small-cell lung cancer--vinorelbine or gemcitabine?
Nature clinical practice. Oncology 2005;2(4):190-1.
2005: Giorgio V Scagliotti
Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer.
Seminars in oncology 2005;32(2 Suppl 2):S5-8.
2005: Thierry Le Chevalier; Rodrigo Arriagada; Jean-Pierre Pignon; Giorgio V Scagliotti
Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?
The lancet oncology 2005;6(3):182-4.
2005: Giorgio V Scagliotti; Cornelius Kortsik; Graham G Dark; Allan Price; Christian Manegold; Rafael Rosell; Mary O'Brien; Patrick M Peterson; Daniel Castellano; Giovanni Selvaggi; Silvia Novello; Johannes Blatter; Louis Kayitalire; Lucio Crino; Luis Paz-Ares
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):690-6.
2005: Giorgio V Scagliotti; Silvia Novello
State of the art in mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 2():ii240-5.
2005: Thierry Le Chevalier; Giorgio V Scagliotti; R Natale; S Danson; Rafael Rosell; R Stahel; P Thomas; Robin Rudd; J Vansteenkiste; N Thatcher; C Manegold; Jean-Louis Pujol; nico van zandwijk; C Gridelli; Jan P van Meerbeeck; Lucio Crino; A Brown; P Fitzgerald; Mike Aristides; J H Schiller
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
Lung cancer (Amsterdam, Netherlands) 2005;47(1):69-80.
2004: Giorgio V Scagliotti; J-Y Douillard
Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;46 Suppl 2():S13-21.
2004: Giorgio V Scagliotti; Silvia Novello
Current development of adjuvant treatment of non-small-cell lung cancer.
Clinical lung cancer 2004;6 Suppl 2():S63-70.
2004: Giorgio V Scagliotti; Silvia Novello; Lucio Crino; Rafael Rosell
Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2004;18(13 Suppl 8):32-7.
2004: Giorgio V Scagliotti; Giovanni Selvaggi; Silvia Novello; Fred R Hirsch
The biology of epidermal growth factor receptor in lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4227s-4232s.
2004: Thomas J Lynch; Alex A. Adjei; Paul A Bunn; Raymond DuBois; David R Gandara; Giuseppe Giaccone; Ramaswamy Govindan; Roy S Herbst; Bruce E Johnson; Fadlo R Khuri; Roman Perez-Soler; Rafael Rosell; Eric K Rowinsky; Alan B Sandler; Giorgio V Scagliotti; Joan H Schiller; Geoffrey I Shapiro; Mark A Socinski; Carol S Hart
Novel agents in the treatment of lung cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4199s-4204s.
2004: Roy S Herbst; Giuseppe Giaccone; Joan H Schiller; Ronald B Natale; Vincent A Miller; Christian Manegold; Giorgio V Scagliotti; Rafael Rosell; Ira Oliff; James A Reeves; Michael K Wolf; Annetta D Krebs; Steven D Averbuch; Judith S Ochs; John Grous; Abderrahim Fandi; David H Johnson
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):785-94.
2004: Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio V Scagliotti; Rafael Rosell; Vincent A Miller; Ronald B Natale; Joan H Schiller; Joachim von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):777-84.
2004: Giovanni Selvaggi; Silvia Novello; Valter Torri; Eugenio Leonardo; Paolo De Giuli; Piero Borasio; C Mossetti; Francesco Ardissone; Paolo Lausi; Giorgio V Scagliotti
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(1):28-32.
2003: Pieter E Postmus; Pierre Rocmans; Hisao Asamura; David Ball; José S A Belderbos; Matteo Cappello; Jacek Jassem; Silvia Novello; Harvey I Pass; Bernward Passlick; Robert Pirker; Neal Ready; William T Sause; Giorgio V Scagliotti; Johan Vansteenkiste; Virginie Westeel; nico van zandwijk
Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;42 Suppl 1():S3-6.
2003: Giorgio V Scagliotti; Silvia Novello
Adjuvant chemotherapy after complete resection for early stage NSCLC.
Lung cancer (Amsterdam, Netherlands) 2003;42 Suppl 1():S47-51.
2003: Giorgio V Scagliotti; Roldano Fossati; Valter Torri; Lucio Crinò; Giuseppe Giaccone; Giovanni Silvano; Massimo Martelli; Maurizia Clerici; Francesco Cognetti; Maurizio Tonato
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Journal of the National Cancer Institute 2003;95(19):1453-61.
2003: Rafael Rosell; Lucio Crino; Kathleen D Danenberg; Giorgio V Scagliotti; Gerold Bepler; Miquel Taron; Vicente Alberola; Mariano Provencio; Carlos Camps; Filippo De Marinis; Jose Javier Sanchez; Ramon Peñas
Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
Seminars in oncology 2003;30(4 Suppl 10):19-25.
2003: Giorgio V Scagliotti; Silvia Novello
Efficacy of neoadjuvant strategies with gemcitabine and other chemotherapy in resectable non-small cell lung cancer: a combined modality approach.
Seminars in oncology 2003;30(4 Suppl 10):13-8.
2003: Paul A Bunn; Frances A Shepherd; Alan B Sandler; Thierry Le Chevalier; Chandra P Belani; Paris A Kosmidis; Giorgio V Scagliotti; Giuseppe Giaccone
Ongoing and future trials of biologic therapies in lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S175-86.
2003: Fred R Hirsch; Giorgio V Scagliotti; Corey J Langer; Marileila Varella-Garcia; Wilbur A Franklin
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.
Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S29-42.
2003: Rafael Rosell; Miquel Taron; Agustí Barnadas; Giorgio V Scagliotti; Carme Sarries; Barbara Roig
Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.
Cancer control : journal of the Moffitt Cancer Center 2003;10(4):297-305.
2003: Federico Cappuzzo; Giovanni Selvaggi; Vanesa Gregorc; Francesca Mazzoni; Maura Betti; Maria Rita Migliorino; Silvia Novello; Antonio Maestri; Filippo De Marinis; Samir Darwish; Verena de Angelis; Fabrizio Nelli; Stefania Bartolini; Giorgio V Scagliotti; Maurizio Tonato; Lucio Crinò
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Cancer 2003;98(1):128-34.
2003: Giorgio V Scagliotti; Silvia Novello
Adjuvant therapy in completely resected non-small-cell lung cancer.
Current oncology reports 2003;5(4):318-25.
2003: Rafael Rosell; Giorgio V Scagliotti; Kathleen D Danenberg; Reginald V N Lord; Gerold Bepler; Silvia Novello; Janine Cooc; Lucio Crinò; José Javier Sánchez; Miquel Taron; Corrado Boni; Filippo De Marinis; Maurizio Tonato; Maurizio Marangolo; Felice Gozzelino; Francesco Di Costanzo; Massimo Rinaldi; Dennis Salonga; Craig Stephens
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Oncogene 2003;22(23):3548-53.
2003: Giorgio V Scagliotti; Silvia Novello
Pemetrexed and its emerging role in the treatment of thoracic malignancies.
Expert opinion on investigational drugs 2003;12(5):853-63.
2003: Giorgio V Scagliotti; Silvia Novello
The dream is almost over...don't worry, look ahead.
Lung cancer (Amsterdam, Netherlands) 2003;40(2):187-90.
2003: Giorgio V Scagliotti; Dong M Shin; Hedy L Kindler; Michael J Vasconcelles; Uwe Keppler; Christian Manegold; Howard Burris; Ulrich Gatzemeier; Johannes Blatter; James T Symanowski; James J Rusthoven
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1556-61.
2003: Giorgio V Scagliotti; Andrew T Turrisi
Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer.
The oncologist 2003;8(4):361-74.
2002: Giorgio V Scagliotti
Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages.
Lung cancer (Amsterdam, Netherlands) 2002;38 Suppl 3():S23-9.
2002: Carme Sarries; Eric Haura; Barbara Roig; Miquel Taron; Albert Abad; Giorgio V Scagliotti; Rafael Rosell
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.
Pharmacogenomics 2002;3(6):763-80.
2002: Giorgio V Scagliotti; Silvia Novello
Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2002;38 Suppl 2():S13-9.
2002: Giorgio V Scagliotti; Filippo De Marinis; Massimo Rinaldi; Lucio Crinò; Cesare Gridelli; S Ricci; E Matano; Corrado Boni; Maurizio Marangolo; G Failla; Giuseppe Altavilla; Vincenzo Adamo; Anna Ceribelli; M Clerici; Francesco Di Costanzo; Luciano Frontini; Maurizio Tonato
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(21):4285-91.
2002: Giorgio V Scagliotti
Tyrosine kinase signal transduction inhibitors. Clinical trials.
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] 2002;1(4):S34-6.
2002: Giovanni Selvaggi; Giorgio V Scagliotti; Valter Torri; Silvia Novello; Eugenio Leonardo; Susanna Cappia; Claudio Mossetti; Francesco Ardissone; Paolo Lausi; Piero Borasio
HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
Cancer 2002;94(10):2669-74.
2001: Giorgio V Scagliotti; Silvia Novello
Role of erythropoietin in the treatment of lung cancer associated anaemia.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 4():S91-4.
2001: Silvia Novello; L Galli; A Antonuzzo; L Crinó; E Pozzi; Giovanni Selvaggi; S Ricci; F Marrocolo; Samir Darwish; S Sorbolini; Maurizio Tonato; Giorgio V Scagliotti
Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;34(2):261-9.
2001: A C Dingemans; J van Ark-Otte; Simone W Span; Giorgio V Scagliotti; Paul Van Der Valk; Pieter E Postmus; Giuseppe Giaccone
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;32(2):117-28.
2000: Massimo Rinaldi; Lucio Crinò; Giorgio V Scagliotti; Anna Maria Mosconi; Filippo De Marinis; C Gridelli; Giovanni Selvaggi; M Della Giulia; Samir Darwish; S Porrozzi; Silvia Novello; Antonio Cipri; R Bartolucci; Cesare Calandri; Maurizio Tonato
A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1295-300.
2000: Giorgio V Scagliotti
Gemcitabine/cisplatin as induction therapy for stage IIIA N2 non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 4):15-9.
1999: Lucio Crinò; Giorgio V Scagliotti; S Ricci; Filippo De Marinis; Massimo Rinaldi; Cesare Gridelli; Anna Ceribelli; R Bianco; Maurizio Marangolo; Francesco Di Costanzo; M Sassi; S Barni; A Ravaioli; Vincenzo Adamo; Luigi Portalone; G Cruciani; A Masotti; G Ferrara; F Gozzelino; Maurizio Tonato
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3522-30.
1999: Lucio Crinò; Anna Maria Mosconi; Giorgio V Scagliotti; G Selvaggi; Silvia Novello; Massimo Rinaldi; M Della Giulia; C Gridelli; A Rossi; Cesare Calandri; Filippo De Marinis; MA Noseda; Maurizio Tonato
Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2081-5.
1999: Giorgio V Scagliotti; L Crinó; E Pozzi; Enrichetta Corgna; Giovanni Selvaggi; Silvia Novello; G Salsano; A Gentile; MA Palladino; F Marracolo; Maurizio Tonato
Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1999;25(1):39-46.
1999: Giorgio V Scagliotti; Silvia Novello; Giovanni Selvaggi
Multidrug resistance in non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 5():S83-6.
1998: Lucio Crinò; Anna Maria Mosconi; Giorgio V Scagliotti; G Selvaggi; Massimo Rinaldi; M Della Giulia; C Gridelli; Cesare Calandri; Filippo De Marinis; MA Noseda; Maurizio Tonato
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.
Seminars in oncology 1998;25(4 Suppl 9):23-6.
1998: Giuseppe Giaccone; Ted A W Splinter; Channa Debruyne; G S Kho; Pilar Lianes; nico van zandwijk; M C Pennucci; Giorgio V Scagliotti; Jan P van Meerbeeck; Q van Hoesel; Desmond Curran; TM Sahmoud; Pieter E Postmus
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2133-41.
1997: Giorgio V Scagliotti; G Ferrari; Silvia Novello
Neo-adjuvant chemotherapy prior to surgery in stage III non-small cell lung cancer.
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Università di Napoli, Secondo ateneo 1997;52(6):531-4.
1997: Giorgio V Scagliotti; Lucio Crinò
Chemotherapy of non-small cell lung cancer.
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Università di Napoli, Secondo ateneo 1997;52(3):287-95.
1997: Giuseppe Giaccone; Pieter E Postmus; Ted A W Splinter; M Diaz-Puente; nico van zandwijk; Giorgio V Scagliotti; Andrea Ardizzoni; Jan P van Meerbeeck; Channa Debruyne
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.
Oncology (Williston Park, N.Y.) 1997;11(4 Suppl 3):11-4.
1997: Lucio Crinò; Giorgio V Scagliotti; Maurizio Marangolo; F Figoli; M Clerici; Filippo De Marinis; F Salvati; G Cruciani; L Dogliotti; F Pucci; A Paccagnella; Vincenzo Adamo; Giuseppe Altavilla; P Incoronato; M Trippetti; Anna Maria Mosconi; A Santucci; S Sorbolini; C Oliva; Maurizio Tonato
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):297-303.
1996: Giorgio V Scagliotti; L Crinó; Ernesto Pozzi; Enrichetta Corgna; M Palladino; P Masiero; V Salsano; A Gentile; Maurizio Tonato
Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
Seminars in oncology 1996;23(6 Suppl 16):80-3.
1996: Pieter E Postmus; Giorgio V Scagliotti; H J Groen; F Gozzelino; J T Burghouts; Desmond Curran; TM Sahmoud; A Kirkpatrick; Giuseppe Giaccone; Ted A W Splinter
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1498-503.
1996: Giorgio V Scagliotti; U Ricardi; L Crinó; E Maranzano; Filippo De Marinis; M G Morandi; L Meacci; M Marangolo; E Emiliani; Giovanni Rosti; F Figoli; G Bolzicco; P Masiero; A Gentile; Maurizio Tonato
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1996;38(6):561-5.
1995: Giuseppe Giaccone; J van Ark-Otte; Giorgio V Scagliotti; G Capranico; Paul Van Der Valk; G Rubio; O Dalesio; R Lopez; F Zunino; J Walboomers
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Biochimica et biophysica acta 1995;1264(3):337-46.
1995: E Gatti; Giorgio V Scagliotti; G Ferrari; Luciano Mutti; Ernesto Pozzi; Alessandra Stacchini; L Fubini; Massimo Aglietta
Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 1995;8(9):1566-71.
1995: Alessandra Stacchini; L Fubini; E Gatti; Luciano Mutti; Wanda Piacibello; Fiorella Sanavio; Giorgio V Scagliotti; E Pozzi; Massimo Aglietta
In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors.
Leukemia 1995;9(4):665-70.
1995: Giorgio V Scagliotti; P Masiero; Ernesto Pozzi
Biological prognostic factors in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S13-25.
1994: E Leonardo; G Valente; Susanna Cappia; Maurizio Cianfriglia; Giuseppe Arancia; Stefania Meschini; Giorgio V Scagliotti
Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57.
International journal of cancer. Journal international du cancer 1994;57(6):841-6.
1994: Maurizio Cianfriglia; M C Willingham; M Tombesi; Giorgio V Scagliotti; G Frasca; Alberto Chersi
P-glycoprotein epitope mapping. I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi-drug-resistant cells.
International journal of cancer. Journal international du cancer 1994;56(1):153-60.
1993: Giorgio V Scagliotti; M Micela; L Gubetta; E Leonardo; Susanna Cappia; Piero Borasio; Ernesto Pozzi
Prognostic significance of Ki67 labelling in resected non small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):363-5.
1992: Spiridione Garbisa; Giorgio V Scagliotti; L Masiero; C Di Francesco; C Caenazzo; Maurizio Onisto; M Micela; William Stetler-Stevenson; L A Liotta
Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy.
Cancer research 1992;52(16):4548-9.
1991: Giorgio V Scagliotti; F Michelotto; G Kalikatzaros; E Leonardo; Susanna Cappia; L Gubetta; Piero Borasio; Ernesto Pozzi
Detection of multidrug resistance associated P-170 glycoprotein in previously untreated non small cell lung cancer.
Anticancer research 1991;11(6):2207-10.
1991: Andrea Ardizzoni; R Rosso; F Salvati; Giorgio V Scagliotti; E Soresi; G Ferrara; C Pennucci; Editta Baldini; A R Cruciani; Antonio Antilli
Combination chemotherapy and interferon alpha 2b in the treatment of advanced non-small-cell lung cancer. The Italian Lung Cancer Task Force (FONICAP).
American journal of clinical oncology 1991;14(2):120-3.
1991: C Albera; I Mabritto; P Ghio; Giorgio V Scagliotti; Ernesto Pozzi
Lymphocyte subpopulations analysis in pleural fluid and peripheral blood in patients with lymphocytic pleural effusions.
Respiration; international review of thoracic diseases 1991;58(2):65-71.
1991: A S Planting; Andrea Ardizzoni; J Estapé; G Giaccone; Giorgio V Scagliotti; T A Splinter; A Kirkpatrick; Otilia Dalesio; J G McVie
Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872.
Cancer chemotherapy and pharmacology 1991;28(2):145-6.
1989: Giorgio V Scagliotti; M Piani; E Gatti; F Gozzelino; C Albera; Ernesto Pozzi
Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 1989;2(8):746-50.
1989: Giorgio V Scagliotti; F Gozzelino; C Albera; G Pescetti
Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1.
Chemotherapy 1989;35(1):64-8.
1986: Giorgio V Scagliotti; F Bardessono; F Gozzelino; C D'Apuzzo; C Albera; G Pescetti
Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1986;5(5):351-5.
1985: Giorgio V Scagliotti; D Lodico; F Gozzelino; F Bardessono; C Albera; E Gatti; G Pescetti
Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide.
Oncology 1985;42(4):224-8.
1984: Giorgio V Scagliotti; D Lodico; F Gozzelino; G Pescetti
Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1984;3(5):324-6.
1980: G Pescetti; F Gozzelino; D Osella; Giorgio V Scagliotti
[Ultrastructure of the pulmonary alveolus. Correlations with the endoalveolar tensioactive system].
Minerva medica 1980;71(2):73-82.